MBX Biosciences, Inc.

Over 194 million Americans are living with at least one chronic illness. Chronic conditions such as obesity and hypoparathyroidism (HP) can have a significant impact on patients, families, caregivers and healthcare systems.    In support of the Biotechnology Innovation Organization’s #FightOfOurLives campaign, we recognize the importance of continued innovation to help address unmet needs for patients living with chronic conditions.    Our team at MBX Biosciences is committed to advancing Precision Endocrine Peptide (PEP)™ therapies with the goal of doing just that specifically for patients and families living with HP and obesity. Learn more about MBX’s fight for patients living with chronic conditions and our innovative pipeline: https://lnkd.in/eqp68Nze     #FightOfOurLives #ChronicDisease #Biotechnology #HealthInnovation #MBXBiosciences 

MBX Biosciences today reported financial results for the second quarter ended June 30, 2026, highlighting recent pipeline and corporate progress, including: • Full Phase 2 results and one-year OLE data presented at ENDO 2026 • Phase 3 trial of once-weekly canvuparatide recruiting and on track to initiate in Q3 2026 • Initial Phase 1 data for MBX 4291, a GLP-1/GIP co- agonist, supports the potential for once-monthly dosing • Nomination of MBX 5765 as amycretin prodrug development candidate • Nomination of MBX 6180 as GLP-1/GIP/GCG triple agonist prodrug development candidate • Executive appointments to support next phase of growth View the press release: https://lnkd.in/e8CaZTtS

At MBX, we’re on a mission to redefine what's possible for people living with obesity and hypoparathyroidism. From discovery through development, every role contributes to bringing innovative science closer to the people who need it most. Interested in making an impact alongside a passionate and purpose-driven team? Explore our open roles: mbxbio.com/careers #Hiring #BiotechCareers #LifeSciences #DrugDevelopment #MBXBiosciences

MBX Biosciences today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company’s new Chief Financial Officer.   Read the announcement: https://lnkd.in/gqtF9W_F

By 2035, 25% of the global population is projected to have obesity.    Meanwhile, many patients discontinue current treatments within 1–2 years – often driven by GI-related tolerability issues – highlighting the need for additional options.    Katherine Saunders, MD, FTOS Co-Founder at FlyteHealth and Clinical Assistant Professor of Medicine at Weill Cornell Medicine, shared these insights and more at our recent Obesity Day for investors.    At MBX Biosciences, we're committed to advancing precision peptide therapies to address these critical challenges for people living with obesity.    View the presentation here: https://lnkd.in/g3mBBiBV 

Join us in building something that matters. At MBX Biosciences, we’re growing our team across Business Development, Finance, IT, Program Management, and Regulatory. If you’re passionate about advancing treatments for endocrine and metabolic disorders, this is your chance to make a real impact alongside a fast-paced, growing, mission-driven team.  Learn about our mission and explore our open roles: mbxbio.com/careers.

As the biotech industry marks 50 years of progress, MBX is proud to support the Biotechnology Innovation Organization’s #FightofOurLives campaign – spotlighting the breakthroughs, patients, and scientists driving innovation forward.   We are proud to be part of an industry that has transformed lives over the past five decades and look forward to contributing to continued progress as we advance scientific innovation for people living with rare endocrine and metabolic diseases through our Precision Endocrine Peptide (PEP)™ platform.   Explore the impact of biotech over the past 50 years: https://lnkd.in/e4zDm6XT

MBX Biosciences today announced full results from the 12-week Avail™ Phase 2 trial and new one-year data from the ongoing open-label extension (OLE) study supporting its once-weekly parathyroid hormone replacement therapy candidate in adult patients with chronic hypoparathyroidism.   Join Company management as they discuss the results, alongside Distinguished Professor of Chemistry at Indiana University Bloomington and MBX scientific co-founder, Richard DiMarchi, Ph.D. and Senior Clinical Advisor at The National Institutes of Health, Michael Collins, M.D. on a webcast of the conference call today (8:00am ET): https://lnkd.in/g3mBBiBV.

June 1 marks #WorldHypoparaDay – an opportunity to spotlight #hypoparathyroidism (HP) and the more than 100,000 people in the U.S. living with this rare endocrine disorder.    At MBX, we’re proud to partner with the HypoPARAthyroidism Association, whose dedicated efforts support patients and families through education, community, research, and advocacy.    While awareness days play an important role, the need for progress in HP extends well beyond a single moment. We remain committed to advancing the science and leveraging our Precision Endocrine Peptide (PEP™) platform to help address the ongoing unmet needs of people living with HP. 

MBX Biosciences will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for our potential once-weekly PTH replacement therapy for hypoparathyroidism (HP) at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026) in Chicago.    Data being presented include:  • 1-year OLE Phase 2 data at the Parathyroid Summit (June 12)  • Full 12-week Avail™ Phase 2 results at ENDO (June 13)    Join Company management, alongside Distinguished Professor of Chemistry at Indiana University Bloomington and MBX scientific co-founder, Richard DiMarchi, Ph.D. and endocrinologist and Senior Clinical Advisor at The National Institutes of Health, Michael Collins, M.D. on the conference call and webcast: https://lnkd.in/g3mBBiBV